Radiation therapy used most often for prostate cancer regardless of decision-making factors
the ONA take:
The most common treatment for prostate cancer is radiation therapy, regardless of cancer stage, prostate-specific antigen (PSA) level, and prognosis and risk rating.
In an analysis of Surveillance, Epidemiology and End Results (SEER)-Medicare linked data for 37,621 men with a prostate cancer diagnosis from 2004 to 2007, the researchers found radiation therapy was the most common treatment, followed by radical prostatectomy and other treatments including watchful waiting or active surveillance (WW-AS).
Radiation treatment was the most common regardless of stage, PSA level, and prognosis and tumor rating; however, PSA level influenced the choice of radical prostatectomy.
Clinical stage, as well as prognosis and tumor rating, influenced patients to choose WW-AS, but cancer stage, PSA level, and prognosis and risk rating prompted a decision to undergo androgen-deprivation therapy (ADT).
The authors reported that increased use of treatments in men with prostate cancer and underuse of active surveillance in men with low-risk disease remain.
Their study concludes that further research into what drives treatment choices among both patients and their physicians are needed.
Most common treatment for prostate cancer is radiation therapy, regardless of cancer stage.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
- Ofatumumab With Fludarabine, Cyclophosphamide Approved for Relapsed CLL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|